title: Epithelial and stromal expression of miRNAs during prostate cancer progression.
abstract: Global microRNA (miRNA) profile may predict prostate cancer (PCa) behaviors. In this study, we examined global miRNA expression by miRNA profiling as well as specific miRNA expression levels in PCa epithelium and stroma by in situ hybridization (ISH) and correlated with various clinicopathological features. We first performed comprehensive miRNA profiling on 27 macrodissected cases of PCa by miRNA microarray. A total of 299 miRNAs were significantly dysregulated in high grade and advanced stage PCa. We demonstrated that PCa can be readily classified into high grade/stage and low-grade/stage groups by its global miRNA expression profile. Next, we examined the expression of several selected dysregulated miRNAs, including let-7c, miR-21, miR-27a, miR-30c, and miR-219, in PCa by ISH. The levels of miRNA expression in epithelial and stromal cells were scored semiquantitatively and compared with clinicopathological features, including age, race, Gleason score, stage, PSA recurrence, metastasis, hormone resistance and survival. We found that the expression of miR-30c and miR-219 were significantly down-regulated in PCa. miR-21 and miR-30c were significantly down-regulated in PCa in African Americans compared to Caucasian Americans. In addition, down-regulation of let-7c, miR-21, miR-30c, and miR-219 are associated with metastatic disease. Furthermore, down-regulation of miR-30c and let-7c are significantly associated with androgen-dependent PCa. In PCa stromal cells, let-7c downregulation is significantly associated with extraprostatic extension. Our data suggest that selected miRNAs may serve as potential biomarkers to predict cancer progression.
authors: Department of Pathology, New York University School of Medicine New York, USA.
authors: Qinghu
authors: Q
authors: Ren
authors: Department of Pathology, New York University School of Medicine New York, USA ; Department of Urology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei Province, China.
authors: Jiaqian
authors: J
authors: Liang
authors: Department of Pathology, Northwestern University School of Medicine Chicago, IL, USA.
authors: Jianjun
authors: J
authors: Wei
authors: Department of Pathology, New York University School of Medicine New York, USA.
authors: Olca
authors: O
authors: Basturk
authors: Department of NYU Cancer Institute, New York University School of Medicine New York, USA.
authors: Jinhua
authors: J
authors: Wang
authors: Department of Pathology, New York University School of Medicine New York, USA.
authors: Garrett
authors: G
authors: Daniels
authors: Department of Pathology, New York University School of Medicine New York, USA.
authors: Lan Lin
authors: LL
authors: Gellert
authors: Department of Pathology, New York University School of Medicine New York, USA.
authors: Yirong
authors: Y
authors: Li
authors: Department of Pathology, New York University School of Medicine New York, USA.
authors: Ying
authors: Y
authors: Shen
authors: Department of Urology, New York University School of Medicine New York, USA.
authors: Iman
authors: I
authors: Osman
authors: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei Province, China.
authors: Jun
authors: J
authors: Zhao
authors: Department of Pathology, New York University School of Medicine New York, USA.
authors: Jonathan
authors: J
authors: Melamed
authors: Department of Pathology, New York University School of Medicine New York, USA ; Department of NYU Cancer Institute, New York University School of Medicine New York, USA ; Department of Urology, New York University School of Medicine New York, USA ; Department of New York Harbor Healthcare System, New York University School of Medicine New York, USA.
authors: Peng
authors: P
authors: Lee
keywords: miRNA; prostate cancer progression